132 related articles for article (PubMed ID: 23754889)
1. Sorafenib in metastatic MTC - a case report and minireview of the literature.
Petrova M; Mihaylova Z; Fakirova A
Int Med Case Rep J; 2010; 3():55-8. PubMed ID: 23754889
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
3. First Line Sorafenib Treatment for Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
Kocsis J; Szekanecz É; Bassam A; Uhlyarik A; Pápai Z; Rubovszky G; Mezősi E; Rucz K; Garai I; Nagy E; Uray I; Horváth Z
Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):240-246. PubMed ID: 29506310
[TBL] [Abstract][Full Text] [Related]
4. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
Dabelić N; Jukić T; Fröbe A
Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Lam ET; Ringel MD; Kloos RT; Prior TW; Knopp MV; Liang J; Sammet S; Hall NC; Wakely PE; Vasko VV; Saji M; Snyder PJ; Wei L; Arbogast D; Collamore M; Wright JJ; Moley JF; Villalona-Calero MA; Shah MH
J Clin Oncol; 2010 May; 28(14):2323-30. PubMed ID: 20368568
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
[TBL] [Abstract][Full Text] [Related]
7. Molecular Targeted Therapies of Aggressive Thyroid Cancer.
Ferrari SM; Fallahi P; Politti U; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A
Front Endocrinol (Lausanne); 2015; 6():176. PubMed ID: 26635725
[TBL] [Abstract][Full Text] [Related]
8. Recent Updates on the Management of Medullary Thyroid Carcinoma.
Kim BH; Kim IJ
Endocrinol Metab (Seoul); 2016 Sep; 31(3):392-399. PubMed ID: 27586449
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies in thyroid cancer: an extensive review of the literature.
Bikas A; Vachhani S; Jensen K; Vasko V; Burman KD
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1299-1313. PubMed ID: 27367142
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib in metastatic thyroid cancer.
Capdevila J; Iglesias L; Halperin I; Segura A; Martínez-Trufero J; Vaz MÁ; Corral J; Obiols G; Grande E; Grau JJ; Tabernero J
Endocr Relat Cancer; 2012 Apr; 19(2):209-16. PubMed ID: 22285864
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population.
Benekli M; Yalcin S; Ozkan M; Elkiran ET; Sevinc A; Cabuk D; Coskun HS; Oksuzoglu B; Bayar B; Akbulat A; Ozet A
Onco Targets Ther; 2015; 8():1-5. PubMed ID: 25548522
[TBL] [Abstract][Full Text] [Related]
12. Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Ruffilli I; Patrizio A; Materazzi G; Antonelli A
Cancer Manag Res; 2019; 11():7893-7907. PubMed ID: 31686907
[TBL] [Abstract][Full Text] [Related]
13. A case of advanced medullary thyroid carcinoma successfully treated with sunitinib.
Bugalho MJ; Domingues R; Borges A
Oncologist; 2009 Nov; 14(11):1083-7. PubMed ID: 19887470
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy for endocrine cancer: the medullary thyroid carcinoma paradigm.
Ye L; Santarpia L; Gagel RF
Endocr Pract; 2009; 15(6):597-604. PubMed ID: 19546050
[TBL] [Abstract][Full Text] [Related]
15. Thyroid carcinoma metastases to axillary lymph nodes: report of two rare cases of papillary and medullary thyroid carcinoma and literature review.
Cummings AL; Goldfarb M
Endocr Pract; 2014 Mar; 20(3):e34-7. PubMed ID: 24246352
[TBL] [Abstract][Full Text] [Related]
16. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
[TBL] [Abstract][Full Text] [Related]
17. Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review.
Al-Jundi M; Thakur S; Gubbi S; Klubo-Gwiezdzinska J
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751138
[TBL] [Abstract][Full Text] [Related]
18. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
Santarpia L; Ye L; Gagel RF
J Intern Med; 2009 Jul; 266(1):99-113. PubMed ID: 19522829
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.
Koh YW; Shah MH; Agarwal K; McCarty SK; Koo BS; Brendel VJ; Wang C; Porter K; Jarjoura D; Saji M; Ringel MD
Endocr Relat Cancer; 2012 Feb; 19(1):29-38. PubMed ID: 22109971
[TBL] [Abstract][Full Text] [Related]
20. Metachronous appearance of second malignancies in medullary thyroid carcinoma (MTC) patients: a diagnostic challenge and brief review of the literature.
Alevizaki M; Kyratzoglou E; Bamias A; Tzanela M; Dimopoulos MA; Saltiki K
Endocrine; 2013 Dec; 44(3):610-5. PubMed ID: 23608930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
